The DOI matches its Crossref record.
Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women
Abstract
A comparative study was done in women and men of the effects of delta 9-tetrahydrocannabinol (delta 9-THC), intravenously or orally, on dynamic activity, metabolism, excretion, and kinetics. In general no differences between the two sexes were observed. delta 9-THC is converted by microsomal hydroxylation to 11-hydroxy-delta 9-THC (11-OH-delta 9-THC), which is both a key intermediate for further metabolism to 11-nor-delta 9-THC-9-carboxylic acid (11-nor-acid) by liver alcohol-dehydrogenase enzymes and a potent psychoactive metabolite. Major differences in the ratio of the concentration of 11-OH-delta 9-THC to that of delta 9-THC in plasma were found after intravenous dosing (ratio 1:10 to 20) compared with oral administration (ratio 0.5 to 1:1). The final metabolic products are the 11-nor-acids and the related, more polar acids. Urinary excretion of delta 9-THC is restricted to acidic nonconjugated and conjugated metabolites. After 72 hr mean cumulative urinary excretion, noted for both routes and for both sexes, ranged from 13% to 17% of the total dose. After 72 hr the cumulative fecal excretion for both sexes after intravenous administration ranged from 25% to 30%; after oral administration the range was 48% to 53%. Metabolites were found in the feces in large concentration in the nonconjugated form; concentrations of 11-OH-delta 9-THC were particularly noteworthy. Kinetics of delta 9-THC and metabolites were much the same for female and male subjects. For delta 9-THC, terminal-phase t1/2s for both sexes, irrespective of the route, ranged from 25 to 36 hr. A comparison of the results for AUC/dose (delta 9-THC) after oral dosing with comparable data from intravenous administration indicated bioavailability of the order of 10% to 20% for both sexes. After intravenous delta 9-THC, large apparent volumes of distribution were noted (about 10 l/kg for both sexes).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pharmacokinetics and Pharmacodynamics of Cannabinoids
Grotenhermen, F. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342040-00003 · Cited by 1,511
Human Cannabinoid Pharmacokinetics
Huestis, M. A. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790152 · Cited by 1,102
D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.-T., Braley, G., Gueorguieva, R., & Krystal, J. H. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300496 · Cited by 1,024
Cannabis: pharmacology and toxicology in animals and humans
ADAMS, I. B., & MARTIN, B. R. (1996) · Addiction · doi:10.1046/j.1360-0443.1996.911115852.x · Cited by 570
Huestis, M. A., Henningfield, J. E., & Cone, E. J. (1992) · Journal of Analytical Toxicology · doi:10.1093/jat/16.5.276 · Cited by 519
The Pharmacologic and Clinical Effects of Medical Cannabis
Borgelt, L. M., Franson, K. L., Nussbaum, A. M., & Wang, G. S. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1187 · Cited by 423
Cannabinoids and Pain: New Insights From Old Molecules
Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01259 · Cited by 376
Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective
Cooper, Z. D., & Craft, R. M. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.140 · Cited by 350
Cannabinoid Hyperemesis Syndrome
A. Galli, J., Andari Sawaya, R., & K. Friedenberg, F. (2011) · Current Drug Abuse Reviewse · doi:10.2174/1874473711104040241 · Cited by 303
Huestis, M. A. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_23 · Cited by 278
Abstinence symptoms following oral THC administration to humans
Haney, M., Ward, A. S., Comer, S. D., Foltin, R. W., & Fischman, M. W. (1999) · Psychopharmacology · doi:10.1007/s002130050848 · Cited by 261
Review of Biologic Matrices (Urine, Blood, Hair) as Indicators of Recent or Ongoing Cannabis Use
Musshoff, F., & Madea, B. (2006) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000197091.07807.22 · Cited by 258
Cannabis use during pregnancy: Pharmacokinetics and effects on child development
Grant, K. S., Petroff, R., Isoherranen, N., Stella, N., & Burbacher, T. M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.014 · Cited by 255
Naef, M., Curatolo, M., Petersen-Felix, S., Arendt-Nielsen, L., Zbinden, A., & Brenneisen, R. (2003) · Pain · doi:10.1016/s0304-3959(03)00163-5 · Cited by 209
“Although THC is almost completely absorbed (90– 95%) after oral administration (Wall et al., 1983; Unimed Pharmaceuticals, 2001) the plasma profiles after 20 mg THC are characterized by very low levels of THC and high concentrations of the two main metabolites 11-OHTHC and 11-COOH-THC.”
BackgroundInfluentialRomero-Sandoval, A., Nutile-McMenemy, N., & DeLeo, J. A. (2008) · Anesthesiology · doi:10.1097/aln.0b013e318167af74 · Cited by 168
The multidrug transporter ABCG2 (BCRP) is inhibited by plant‐derived cannabinoids
Holland, M. L., Lau, D. T. T., Allen, J. D., & Arnold, J. C. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707467 · Cited by 150
Sex differences in substance use disorders: focus on side effects
Agabio, R., Campesi, I., Pisanu, C., Gessa, G. L., & Franconi, F. (2016) · Addiction Biology · doi:10.1111/adb.12395 · Cited by 117
Antitumorigenic effects of cannabinoids beyond apoptosis.
Freimuth, N., Ramer, R., & Hinz, B. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.157735 · Cited by 71
Metadata
- Authors
- Wall, M. E., Sadler, B. M., Brine, D., Taylor, H., & Perez-Reyes, M.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1983-09
- Volume
- 34
- Issue
- 3
- Pages
- 352-363
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2116460935
- Cited by
- 345
- References
- 0
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.